TechCrunchData Collective and SynBioBeta founder John Cumbers launch a seed stage biotech fundTechCrunchData Collective (DCVC) is bringing Dr. John Cumbers, the founder of synthetic biology platform SynBioBeta and setting him up with his own biotech fu… Continue reading
TechCrunchData Collective and SynBioBeta founder John Cumbers launch a seed stage biotech fundTechCrunchData Collective (DCVC) is bringing Dr. John Cumbers, the founder of synthetic biology platform SynBioBeta and setting him up with his own biotech fu… Continue reading
|
Pioneering Investigators in Experimental Heart Stem Cell and Cancer Therapies Recognized
Newswise (press release) Newswise — LOS ANGELES (April 4, 2017) – Two prominent Cedars-Sinai investigators — one leading the development of biological treatments for heart disease, the other spearheading the design and analysis of clinical trials for cancer research — were … |
|
Pioneering Investigators in Experimental Heart Stem Cell and Cancer Therapies Recognized
Newswise (press release) Newswise — LOS ANGELES (April 4, 2017) – Two prominent Cedars-Sinai investigators — one leading the development of biological treatments for heart disease, the other spearheading the design and analysis of clinical trials for cancer research — were … |
|
Pioneering Investigators in Experimental Heart Stem Cell and Cancer Therapies Recognized
Newswise (press release) Newswise — LOS ANGELES (April 4, 2017) – Two prominent Cedars-Sinai investigators — one leading the development of biological treatments for heart disease, the other spearheading the design and analysis of clinical trials for cancer research — were … |
Arizona Daily Star |
Breast Cancer ‘Immunotherapy‘ Helps Some With Tough-to-Treat Disease
Arizona Daily Star MONDAY, April 3, 2017 (HealthDay News) — Women with a particularly aggressive form of breast cancer who responded to an new immune-focused drug gained a significant survival benefit, a new study shows. The patients all had what’s known as advanced … Immunotherapy May Treat This Deadly Breast CancerTIME Immunotherapy Shows Early Promise in Triple-Negative Breast CancerR & D Magazine First Survival Results With Immunotherapy, TNBCMedscape MilTech –OncLive all 16 news articles » |
Xconomy |
Angionetics Nears Key Gene Therapy Trial for Coronary Heart Disease
Xconomy Christopher Reinhard will tell you there is nothing unusual about the 20-plus years he’s spent getting an experimental heart therapy to late-stage clinical trials. “Very rarely will you get a short story on development of a drug,” said Reinhard (above … |